Lilly to acquire ImClone « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Lilly to acquire ImClone

Posted on October 6, 2008 by crimsoncanary

Eli Lilly has announced that it will acquire ImClone Systems through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

Filed under: Uncategorized | Tagged: Acquisition, BMS, cetuximab, erbitux, HER1, ImClone, kinase, Lilly, Merck KGaA, Merck-Serono

« Benzoxoloazepinolone (CID755673) is a potent Protein kinase D inhibitor Scripps Inst publish series of Rho kinase II inhibitors »